TR201908638T4 - Ang2 bağlayıcı moleküller. - Google Patents

Ang2 bağlayıcı moleküller. Download PDF

Info

Publication number: TR201908638T4
Authority: TR; Turkey
Prior art keywords: binding molecules; ang2 binding; ang2; vhhs; angiogenesis
Prior art date: 2012-03-30

Application number

TR2019/08638T

Other languages

English (en)

Turkish (tr)

Inventor

Borges Eric

Gschwind Andreas

Georg Ott Rene

Buyse Marie-Ange

Boucneau Joachim

Merchiers Pascal

Depla Erik

Stevenaert Frederik

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-30

Filing date

2013-03-27

Publication date

2019-07-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190468&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201908638(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-03-27 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2019-07-22 Publication of TR201908638T4 publication Critical patent/TR201908638T4/tr

Links

102100034608 Angiopoietin-2 Human genes 0.000 title abstract 5
101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 title abstract 5
108060003951 Immunoglobulin Proteins 0.000 abstract 1
230000033115 angiogenesis Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
102000018358 immunoglobulin Human genes 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gynecology & Obstetrics (AREA)
Mycology (AREA)
Gastroenterology & Hepatology (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Ophthalmology & Optometry (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

TR2019/08638T 2012-03-30 2013-03-27 Ang2 bağlayıcı moleküller. TR201908638T4 (tr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP12162615		2012-03-30

Publications (1)

Publication Number	Publication Date
TR201908638T4 true TR201908638T4 (tr)	2019-07-22

Family

ID=48190468

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TR2019/08638T TR201908638T4 (tr)	2012-03-30	2013-03-27	Ang2 bağlayıcı moleküller.

Country Status (27)

Country	Link
US (5)	US20130259859A1 (es)
EP (1)	EP2831111B1 (es)
JP (1)	JP5970734B2 (es)
KR (1)	KR102020255B1 (es)
CN (1)	CN104321344B (es)
AU (1)	AU2013241769B2 (es)
BR (1)	BR112014023415B1 (es)
CA (1)	CA2865464C (es)
CL (1)	CL2014002393A1 (es)
CY (1)	CY1122007T1 (es)
DK (1)	DK2831111T3 (es)
EA (1)	EA031182B1 (es)
ES (1)	ES2729165T3 (es)
HR (1)	HRP20190817T1 (es)
HU (1)	HUE044263T2 (es)
IL (1)	IL234234B (es)
IN (1)	IN2014DN06904A (es)
LT (1)	LT2831111T (es)
MX (1)	MX350248B (es)
NZ (1)	NZ628584A (es)
PH (1)	PH12014502179B1 (es)
PL (1)	PL2831111T3 (es)
PT (1)	PT2831111T (es)
RS (1)	RS58732B1 (es)
SI (1)	SI2831111T1 (es)
TR (1)	TR201908638T4 (es)
WO (1)	WO2013144266A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
CA2963091A1 (en)	2014-10-06	2016-04-14	Dana-Farber Cancer Institute, Inc.	Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
AU2015331602A1 (en)	2014-10-17	2017-04-27	Amgen Inc.	Antibodies directed to angiopoietin-1 and angiopoietin-2 for ocular therapies
SG11201706840WA (en) *	2015-03-31	2017-09-28	Vhsquared Ltd	Peptide construct having a protease-cleavable linker
CN107849126B (zh) *	2015-07-29	2022-04-08	阿勒根公司	仅有重链的抗ang-2抗体
CA3040194A1 (en) *	2016-10-13	2018-04-19	Dana-Farber Cancer Institute, Inc.	Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
KR102143132B1 (ko) *	2016-12-26	2020-08-10	기초과학연구원	항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물
US10537637B2 (en)	2017-01-05	2020-01-21	Gensun Biopharma Inc.	Checkpoint regulator antagonists
WO2018220169A1 (en) *	2017-06-02	2018-12-06	Boehringer Ingelheim International Gmbh	Anti-cancer combination therapy
CN108659130B (zh) *	2018-05-28	2021-09-10	长春力太生物技术有限公司	一种抗癌胚抗原纳米抗体及其应用
JP2021529556A (ja)	2018-06-29	2021-11-04	ジェンサンバイオファーマ、インコーポレイテッドＧｅｎｓｕｎＢｉｏｐｈａｒｍａ，Ｉｎｃ．	抗腫瘍アンタゴニスト
KR102527315B1 (ko) *	2019-02-25	2023-05-03	주식회사 파멥신	항-Ang2 항체 및 이의 용도
US20220185875A1 (en) *	2019-03-18	2022-06-16	Jiangsu Hengrui Medicine Co., Ltd.	Bispecific antibody specifically bound to vegf and ang2
CN114340735A (zh)	2019-06-28	2022-04-12	璟尚生物制药公司	突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
CN111875706B (zh) *	2020-07-16	2021-03-30	广州康盛生物科技股份有限公司	一种抗人IgE蛋白的单域抗体及其应用
US20220389120A1 (en)	2021-06-03	2022-12-08	Gensun Biopharma Inc.	Multispecific antagonists
AU2021463580A1 (en) *	2021-09-10	2024-04-11	Soter Biopharma Pte. Ltd.	Anti-ang2 antibody, preparation method therefor, and application thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE427968T1 (de)	1992-08-21	2009-04-15	Univ Bruxelles	Immunoglobuline ohne leichtkette
US5643755A (en)	1994-10-07	1997-07-01	Regeneron Pharmaceuticals Inc.	Nucleic acid encoding tie-2 ligand
US5814464A (en)	1994-10-07	1998-09-29	Regeneron Pharma	Nucleic acids encoding TIE-2 ligand-2
US6329516B1 (en)	1997-04-28	2001-12-11	Fmc Corporation	Lepidopteran GABA-gated chloride channels
JP2004525620A (ja)	2001-01-17	2004-08-26	トルビオン・ファーマシューティカルズ・インコーポレイテッド	結合ドメイン−免疫グロブリン融合タンパク質
JP4303105B2 (ja)	2001-06-28	2009-07-29	ドマンティスリミテッド	二重特異性リガンドとその利用
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
US7205275B2 (en)	2001-10-11	2007-04-17	Amgen Inc.	Methods of treatment using specific binding agents of human angiopoietin-2
JP2006520584A (ja)	2002-11-08	2006-09-14	アブリンクスエン．ヴェー．	安定化単一ドメイン抗体
EP1558645B1 (en)	2002-11-08	2011-07-27	Ablynx N.V.	Stabilized single domain antibodies in pharmaceutical composition adapted for inhalation
DE60334645D1 (de)	2003-11-07	2010-12-02	Ablynx Nv	Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US20050284249A1 (en)	2004-06-29	2005-12-29	Arnone David F	Worm type gear mover assembly
JP5113523B2 (ja)	2004-10-13	2013-01-09	アブリンクスナームローゼフェンノートシャップ	アミロイド−βに対するナノ抗体及びアルツハイマー病のような神経変性疾患の治療のためのナノ抗体ＴＭを含むポリペプチド
US7973140B2 (en)	2004-12-21	2011-07-05	Medimmune Limited	Antibodies directed to angiopoietin-2 and uses thereof
DK2949668T3 (da)	2005-05-18	2019-11-11	Ablynx Nv	Forbedrede nanobodies tm mod tumornekrosefaktor-alfa
RU2008152435A (ru)	2006-06-06	2010-07-20	Дженентек, Инк. (Us)	Композиции и способы регулирования развития сосудов
WO2008020079A1 (en)	2006-08-18	2008-02-21	Ablynx N.V.	Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling
CA2678218A1 (en)	2007-02-21	2008-08-28	Ablynx N.V.	Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
CA2717015A1 (en)	2008-03-05	2009-09-11	Ablynx Nv	Novel antigen binding dimer-complexes, methods of making and uses thereof
WO2009147248A2 (en) *	2008-06-05	2009-12-10	Ablynx N.V.	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
AU2009324354B2 (en) *	2008-12-10	2016-04-14	Ablynx Nv	Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
JO3182B1 (ar) *	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US9527925B2 (en) *	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) *	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2

2013
- 2013-03-27 JP JP2015502346A patent/JP5970734B2/ja active Active
- 2013-03-27 RS RS20190627A patent/RS58732B1/sr unknown
- 2013-03-27 PT PT13718796T patent/PT2831111T/pt unknown
- 2013-03-27 AU AU2013241769A patent/AU2013241769B2/en active Active
- 2013-03-27 DK DK13718796.9T patent/DK2831111T3/en active
- 2013-03-27 HU HUE13718796 patent/HUE044263T2/hu unknown
- 2013-03-27 ES ES13718796T patent/ES2729165T3/es active Active
- 2013-03-27 SI SI201331449T patent/SI2831111T1/sl unknown
- 2013-03-27 TR TR2019/08638T patent/TR201908638T4/tr unknown
- 2013-03-27 IN IN6904DEN2014 patent/IN2014DN06904A/en unknown
- 2013-03-27 EA EA201401065A patent/EA031182B1/ru not_active IP Right Cessation
- 2013-03-27 LT LTEP13718796.9T patent/LT2831111T/lt unknown
- 2013-03-27 KR KR1020147028419A patent/KR102020255B1/ko active IP Right Grant
- 2013-03-27 EP EP13718796.9A patent/EP2831111B1/en active Active
- 2013-03-27 BR BR112014023415-9A patent/BR112014023415B1/pt active IP Right Grant
- 2013-03-27 CN CN201380026471.3A patent/CN104321344B/zh active Active
- 2013-03-27 PL PL13718796T patent/PL2831111T3/pl unknown
- 2013-03-27 MX MX2014011171A patent/MX350248B/es active IP Right Grant
- 2013-03-27 CA CA2865464A patent/CA2865464C/en active Active
- 2013-03-27 WO PCT/EP2013/056635 patent/WO2013144266A1/en active Application Filing
- 2013-03-27 NZ NZ628584A patent/NZ628584A/en unknown
- 2013-03-28 US US13/852,402 patent/US20130259859A1/en not_active Abandoned
2014
- 2014-08-21 IL IL234234A patent/IL234234B/en active IP Right Grant
- 2014-09-10 CL CL2014002393A patent/CL2014002393A1/es unknown
- 2014-09-29 PH PH12014502179A patent/PH12014502179B1/en unknown
2016
- 2016-12-21 US US15/386,181 patent/US20170107281A1/en not_active Abandoned
2018
- 2018-07-02 US US16/025,067 patent/US20190135907A1/en not_active Abandoned
2019
- 2019-04-30 HR HRP20190817TT patent/HRP20190817T1/hr unknown
- 2019-06-18 CY CY20191100625T patent/CY1122007T1/el unknown
2020
- 2020-03-13 US US16/817,700 patent/US20200207845A1/en not_active Abandoned
2023
- 2023-03-17 US US18/185,493 patent/US20230203146A1/en active Pending

Also Published As

Publication number	Publication date
NZ628584A (en)	2016-04-29
JP5970734B2 (ja)	2016-08-17
US20130259859A1 (en)	2013-10-03
CN104321344A (zh)	2015-01-28
PH12014502179A1 (en)	2014-12-10
BR112014023415B1 (pt)	2022-04-12
HRP20190817T1 (hr)	2019-06-28
MX350248B (es)	2017-08-31
AU2013241769A1 (en)	2014-08-28
IL234234B (en)	2020-06-30
EA201401065A1 (ru)	2015-03-31
CA2865464C (en)	2022-07-12
KR102020255B1 (ko)	2019-09-10
CA2865464A1 (en)	2013-10-03
EP2831111A1 (en)	2015-02-04
US20170107281A1 (en)	2017-04-20
EP2831111B1 (en)	2019-03-20
KR20140146606A (ko)	2014-12-26
US20230203146A1 (en)	2023-06-29
PH12014502179B1 (en)	2014-12-10
CN104321344B (zh)	2017-11-21
JP2015516805A (ja)	2015-06-18
SI2831111T1 (sl)	2019-06-28
BR112014023415A2 (pt)	2017-07-11
HUE044263T2 (hu)	2019-10-28
AU2013241769B2 (en)	2017-05-11
MX2014011171A (es)	2015-03-06
DK2831111T3 (en)	2019-04-29
LT2831111T (lt)	2019-05-10
US20200207845A1 (en)	2020-07-02
PL2831111T3 (pl)	2019-09-30
IN2014DN06904A (es)	2015-05-15
RS58732B1 (sr)	2019-06-28
ES2729165T3 (es)	2019-10-30
WO2013144266A1 (en)	2013-10-03
CL2014002393A1 (es)	2015-01-23
CY1122007T1 (el)	2020-10-14
US20190135907A1 (en)	2019-05-09
EA031182B1 (ru)	2018-11-30
PT2831111T (pt)	2019-05-31

Publication	Publication Date	Title
TR201908638T4 (tr)	2019-07-22	Ang2 bağlayıcı moleküller.
TN2013000390A1 (en)	2015-01-20	Bispecific binding molecules binding to vegf and ang2
SA518400424B1 (ar)	2022-08-17	جزيئات الجسم المضاد لعلاج السرطان
MX353813B (es)	2018-01-31	Moleculas de union a vegf.
EA201890729A1 (ru)	2018-09-28	Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
TN2012000144A1 (en)	2013-09-19	Dll4-binding molecules
WO2015109124A3 (en)	2015-09-24	Immunomodulatory agents
EA201200548A1 (ru)	2012-12-28	Биспецифические связывающие молекулы для антиангиогенезной терапии
BR112014028785A2 (pt)	2017-07-18	proteínas de ligação a antígeno de st2
AR090047A1 (es)	2014-10-15	Dominio variable dual de inmunoglobulinas y sus usos
PH12019500571A1 (en)	2019-08-19	Anti-pd-1 antibodies
TN2013000389A1 (en)	2015-01-20	BISPECIFIC BINDING MOLECULES BINDING TO Dll4 AND Ang2
EA201992136A1 (ru)	2020-02-18	Антитела против pd-l1